1鏈?鏃ワ紝紺兼潵鍒惰嵂瀹ｅ竷錛屽叾鎶楄偪鐦ゆ柊鑽敮鎷?sup>®(闃胯礉瑗垮埄鐗?鑾峰緱鍥藉鑽搧鐩戠潱綆＄悊灞€(NMPA)鎵瑰噯錛屾垚涓哄浗鍐呴涓笖鍞竴琚壒鍑嗙敤浜庢棭鏈熶鉤鑵虹檶鎮ｈ€呯殑CDK4 & 6鎶戝埗鍓傘€傝繖涔熸槸鍞嫨^®(闃胯礉瑗垮埄鐗?緇?020騫?2鏈堣幏寰桸MPA鎵瑰噯鐢ㄤ簬娌葷枟HR+, HER2-鐨勫眬閮ㄦ櫄鏈熸垨杞Щ鎬т鉤鑵虹檶鍚庯紝鍐嶆鑾鋒壒鏂伴€傚簲鐥囥€?/p>

涔寵吅鐧屾槸鍏ㄧ悆濂蟲€т腑鏈€楂樺彂鐨勭檶鐥?sup>1銆傛嵁浼拌錛?0%鐨勪鉤鑵虹檶紜瘖鍦ㄦ棭鏈?sup>2銆傚叾涓渶甯歌鐨勪簹鍨嬩負HR+, HER2-鍨嬶紝綰﹀崰涔寵吅鐧屾偅鑰呮€繪暟鐨?0%³銆傚湪紜瘖HR+, HER2-鏃╂湡涔寵吅鐧岀殑浜虹兢涓紝綰?0%鐨勬偅鑰呭瓨鍦ㄧ檶鐥囧鍙戜箖鑷寵繘灞曚負涓嶅彲娌繪剤鐨勮漿縐葷檶鐨勯闄?sup>4銆?/p>

姝ゆ鍞嫨^®(闃胯礉瑗垮埄鐗?鑾鋒壒鑱斿悎鍐呭垎娉屾不鐤?浠栬帿鏄旇姮鎴栬姵棣欏寲閰舵姂鍒跺墏)閫傜敤浜庢縺绱犲彈浣?HR)闃蟲€с€佷漢琛ㄧ毊鐢熼暱鍥犲瓙鍙椾綋2(HER2)闃存€с€佹穻宸寸粨闃蟲€э紝楂樺鍙戦闄╀笖Ki-67≥20%鏃╂湡涔寵吅鐧屾垚浜烘偅鑰呯殑杈呭姪娌葷枟銆傝閫傚簲鐥囩殑鑾鋒壒鍩轟簬涓€欏歸殢鏈哄涓績III鏈熶復搴婄爺絀?mdash;—monarchE鐨勭爺絀剁粨鏋溿€?/p>

浣滀負monarchE鐮旂┒涓浗涓昏鐮旂┒鑰咃紝澶嶆棪澶у闄勫睘鑲跨槫鍖婚櫌閭靛織鏁忔暀鎺堟寚鍑猴紝“鍦–DK4 & 6鎶戝埗鍓傛棭鏈熶鉤鑵虹檶杈呭姪娌葷枟鐨処II鏈熶復搴婅瘯楠屼腑錛宮onarchE鏄洰鍓嶅敮涓€鍙栧緱闃蟲€х粨鏋滅殑鐮旂┒銆傚緱鐩婁簬涓浗鐮旂┒鑰呭monarchE鐮旂┒鐨勭獊鍑鴻礎鐚紝涓浗鎴愪負棣栨壒鎵瑰噯鍞嫨^®(闃胯礉瑗垮埄鐗?鏃╂湡涔寵吅鐧岄€傚簲鐥囩殑鍥藉涔嬩竴銆傚敮鎷?sup>®(闃胯礉瑗垮埄鐗?鏂伴€傚簲鐥囪幏鎵癸紝灝嗗紑鍒汬R+, HER2-鏃╂湡涔寵吅鐧岄珮鍗辨偅鑰呰緟鍔╂不鐤楁柊鏃朵唬錛屽甫鏉ユ洿澶氭不鎰堢殑甯屾湜銆?rdquo;

鏍規嵁鍥介檯鐧岀棁鐮旂┒鏈烘瀯(International Agency Research on Cancer)緇熻鏁版嵁鏄劇ず錛?020騫翠腑鍥芥柊鍙戜鉤鑵虹檶鐥呬緥綰?1.6涓囷紝姝諱骸鐥呬緥綰?1.7涓囷紝綰﹀崰鍏ㄧ悆涔寵吅鐧屾浜＄梾渚嬬殑17.1%⁵銆傜ぜ鏉ヤ腑鍥芥€昏鍏兼€葷粡鐞嗗紺兼枃鍏堢敓鎸囧嚭錛屾嬈″敮鎷?sup>®(闃胯礉瑗垮埄鐗?鑾鋒壒鏃╂湡涔寵吅鐧岄€傚簲鐥囷紝灝嗗紑鍚棭鏈?鏅氭湡涔寵吅鐧屽叏紼嬬鐞嗙殑鏂扮瘒绔狅紝涓轟腑鍥界殑涔寵吅鐧屾偅鑰呭甫鏉ユ柊鐨勬不鐤楅€夋嫨銆?/p>

紺兼潵涓浗楂樼駭鍓€昏鑽墿鍙戝睍鍙婂尰瀛︿簨鍔′腑蹇冭礋璐ｄ漢鐜嬭帀鍗氬＋鎸囧嚭錛屼腑鍥芥槸monarchE鐮旂┒鍏ㄧ悆浜氱粍璐＄尞鏈€澶氱梾渚嬫暟鎹殑鍥藉涔嬩竴錛屼負鍞嫨^®(闃胯礉瑗垮埄鐗?鏃╂湡涔寵吅鐧岄€傚簲鐥囧湪鍏ㄧ悆鍜屼腑鍥界殑鑾鋒壒鎻愪緵浜嗗己鏈夊姏鐨勭枟鏁堝拰瀹夊叏鎬т緷鎹紝鎴戜滑灝嗘帹鍔ㄦ洿澶氬垱鏂版不鐤楁柟妗堝湪涓浗鐨勫姞閫熻惤鍦般€?/p>

鍙傝€冩枃鐚細

[1] World Health Organization. Breast cancer: prevention and control.

[2] Howlader N, et al. SEER Cancer Statistics Review, 1975-2013. http://seer.cancer.gov/csr/1975_2013/. Accessed: September 8, 2020.

[3] Howlader N, Altekruse S, Li C. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5).

[4] Reinert T and Barrios CH. Optimal Management of Hormone Receptor Positive Metastatic Breast Cancer in 2016. Ther Adv Med Oncol. 2015;7(6):304-20.

[5] Global Cancer. IARC.2020. https://gco.larc.fr